Vacuna Bcg Recien Nacido Immune Mechanisms And Practices

Published

Table of Contents

The BCG vaccine stands as a cornerstone in neonatal immunization, offering critical protection against tuberculosis while eliciting broader immunological benefits. Administered shortly after birth, this live attenuated vaccine derived from Mycobacterium bovis triggers a cascade of immune responses in newborns, including Th1/Th2 cell differentiation and the production of cytokines such as IFN-γ, IL-12, and TNF-α. Since its development by Calmette and Guérin in 1921, the BCG vaccine has undergone refinements, with modern formulations like the Danish 1331 and Tokyo 172 strains demonstrating variable efficacy across global populations. Beyond its primary role in tuberculosis prevention, emerging evidence suggests BCG may confer non-specific immune training, reducing susceptibility to other infections in early life.

This discussion explores the scientific underpinnings of BCG vaccination in newborns, from its biological mechanisms to administration protocols and real-world efficacy. Key considerations include strain-specific immunological profiles, standardized injection techniques, and post-vaccination monitoring to distinguish normal reactions from adverse events. Additionally, the analysis examines the vaccine’s limitations—such as variable protection against pulmonary tuberculosis and challenges in high-risk populations—and proposes strategies to optimize its impact in high-burden settings.

Vacuna Bcg Recién Nacido

Scientific Background of the BCG Vaccine in Newborns: Immunological Mechanisms and Historical Development

The Bacillus Calmette-Guérin (BCG) vaccine remains the sole licensed vaccine for tuberculosis (TB) prevention in infants, leveraging a live attenuated strain of Mycobacterium bovis to induce robust, long-lasting immunity. Its efficacy in newborns stems from a complex interplay of innate and adaptive immune responses, primarily mediated through Th1 cell differentiation and pro-inflammatory cytokine production. Understanding these mechanisms—alongside the vaccine’s evolutionary adaptations from its 1921 origins to modern strains—provides critical insights into its role in pediatric TB prophylaxis and broader non-specific immune training.

Biological Mechanism of BCG-Induced Immunity in Newborns

The BCG vaccine triggers a multi-stage immune response in newborns, beginning with the phagocytosis of Mycobacterium bovis by antigen-presenting cells (APCs) such as dendritic cells and macrophages. The vaccine’s attenuated nature ensures controlled replication within these cells, enabling sustained antigen presentation to naive T cells in lymph nodes. This process polarizes the immune response toward a Th1-dominant profile, characterized by the secretion of key cytokines:

- Interferon-gamma (IFN-γ): Stimulates macrophage activation, enhancing bactericidal activity via reactive oxygen and nitrogen intermediates.

  • Interleukin-12 (IL-12): Promotes Th1 differentiation from naive CD4+ T cells, counteracting Th2-biased responses that could impair mycobacterial control.
  • Tumor Necrosis Factor-alpha (TNF-α): Mediates granuloma formation, a hallmark of mycobacterial containment, while also contributing to systemic inflammation.
  • In newborns, who exhibit immature Th1 responses compared to adults, BCG vaccination induces a shift toward Th1 polarization through IL-12 and IFN-γ signaling, despite initial dominance by regulatory T cells (Tregs) and Th2 cytokines (e.g., IL-4, IL-10). This immunological "training" not only targets Mycobacterium tuberculosis but also confers non-specific protection against unrelated infections, a phenomenon attributed to trained innate immunity.

    Chronological Overview of BCG Vaccine Development

    The BCG vaccine’s origins trace back to 1908, when Albert Calmette and Camille Guérin initiated attenuation of M. bovis through serial subculturing on potato bile media. After 13 years of passaging (1921), the strain—designated BCG (Bacillus Calmette-Guérin)—lost virulence while retaining immunogenicity. Early clinical trials in 1924 demonstrated safety and efficacy in infants, leading to its first widespread use in France (1927). Key milestones in its evolution include:

    - 1930s–1940s: Expansion to Europe and Latin America, with variations in subculture passages (e.g., Danish 1331, derived from the 13th passage).

  • 1970s–1980s: Development of Tokyo 172, a strain with enhanced stability and reduced local reactions, adopted in Japan and later globally.
  • 1990s–Present: Standardization of lyophilized formulations for cold-chain distribution, alongside research into genomic stability and adjuvant-enhanced BCG (e.g., IC31, AS01E) to improve efficacy against pulmonary TB.
  • Modern BCG strains retain the core genetic backbone of M. bovis but exhibit strain-specific differences in growth rate, immunogenicity, and side-effect profiles, influencing their global adoption.

    Comparative Analysis of BCG Strains Used in Newborns

    While all BCG strains share the same attenuated M. bovis lineage, variations in subculturing and regional adaptations have led to distinct immunological and safety profiles. The following table summarizes the most widely used strains, emphasizing their origin, key immunological features, and common neonatal side effects:
    Strain Name Origin Key Immunological Features Common Side Effects in Newborns
    Danish 1331 Statens Serum Institut, Denmark (13th passage)
    • High IFN-γ induction; robust Th1 polarization.
    • Stable in liquid and lyophilized forms.
    • Used in WHO-recommended formulations (e.g., SSI BCG).
    • Local ulceration (1–5%).
    • Regional lymphadenitis (0.1–1%).
    • Systemic reactions (fever, irritability) in <1% of cases.
    Tokyo 172 Japan (172nd passage, derived from Danish 1331)
    • Slower growth rate; reduced local reactogenicity.
    • Lower IL-12 production but comparable IFN-γ levels.
    • Preferred in Japan, Brazil, and some African countries.
    • Lower ulceration rates (<1%).
    • Minimal lymphadenitis (<0.1%).
    • Rare systemic effects; better tolerated in preterm infants.
    Russia (1st Passage) Russia (1st passage, direct from Calmette’s strain)
    • Higher virulence potential; stronger cellular immune response.
    • Used in Eastern Europe and former Soviet states.
    • Associated with higher local reactions.
    • Ulceration rates up to 10%.
    • Frequent lymphadenitis (1–5%).
    • Not recommended for widespread use due to safety concerns.
    Pasteur (France) Institut Pasteur, France (11th passage)
    • Intermediate immunogenicity between Danish and Tokyo strains.
    • Used historically in France and Africa.
    • Moderate ulceration (3–7%).
    • Lymphadenitis in ~0.5% of cases.

    World Health Organization’s 2023 Position on BCG Vaccination in Newborns

    The World Health Organization (WHO) reaffirmed in its 2023 Strategic Advisory Group of Experts (SAGE) recommendations that BCG vaccination remains a cornerstone of TB control in infants, particularly in high-burden settings. The primary objectives include:

    >

    > "BCG is the only licensed vaccine for preventing severe forms of tuberculosis in children, including tuberculous meningitis and miliary TB. Its administration at birth is critical in regions with high TB-HIV co-infection rates, where the risk of disseminated disease is markedly elevated. Beyond TB-specific immunity, BCG induces trained innate immunity, reducing all-cause mortality by up to 20% in low-resource settings, independent of its mycobacterial efficacy."
    >
    Key secondary benefits highlighted by the WHO include:
  • Non-specific immune training: BCG modulates innate immune memory, enhancing responses to vaccines (e.g., measles, polio) and reducing sepsis-related mortality.
  • HIV progression mitigation: BCG reduces TB-related morbidity in HIV-exposed infants, though it does not prevent HIV acquisition.
  • Cost-effectiveness: With a cost per dose <$1 USD, BCG offers unparalleled value in neonatal TB prevention programs.
  • The WHO emphasizes strain selection based on local safety profiles (e.g., Tokyo 172 for preterm infants) and routine administration at birth, with catch-up vaccination for missed opportunities. Research into next-generation BCG formulations (e.g., adjuvanted or genetically modified strains) continues to explore enhanced protection against pulmonary TB in adolescents and adults.

    Vacuna Bcg Recién Nacido - Ilustrasi 2

    Administration Protocols and Best Practices for BCG Vaccination in Newborns

    The Bacillus Calmette-Guérin (BCG) vaccine is administered intradermally to newborns within the first weeks of life as a primary strategy for tuberculosis (TB) prevention. Proper administration ensures optimal immune response while minimizing complications. Standardized protocols for injection technique, pre-vaccination assessments, and post-vaccination monitoring are critical to maintaining safety and efficacy. This section outlines evidence-based guidelines for healthcare providers, emphasizing technical precision, contraindication screening, and clinical follow-up.

    Standardized Injection Technique and Site Selection

    The BCG vaccine must be administered intradermally to elicit the desired immune response. Subcutaneous or intramuscular administration may reduce efficacy and increase adverse reactions. The preferred site is the left upper arm (deltoid region), as it is easily accessible and allows for visual confirmation of correct injection depth. The needle gauge should be 25–26G, and the volume should not exceed 0.05–0.1 mL (0.1 mL is standard for most formulations, including the widely used BCG-SSI or BCG-Danish strains).

    Visual and tactile confirmation of intradermal administration:

  • A small bleb (6–10 mm) should form immediately upon injection, indicating proper placement in the dermis.
  • The needle should be inserted bevel-up at a 5–15° angle, with the bevel facing upward to avoid penetrating deeper layers.
  • Aspiration is unnecessary for BCG, as it is not a blood-containing vaccine. Resistance to injection (rather than smooth flow) confirms intradermal placement.
  • Do not massage the site post-injection, as this may disperse the vaccine and reduce local immune activation.
  • Key anatomical landmarks for injection:

  • The deltoid muscle lies just below the acromion process of the scapula. The injection should be administered 2–3 cm below the acromion and 2–3 cm lateral to the mid-clavicular line, targeting the superficial dermal layer.
  • Avoid injecting over lymph nodes, scars, or areas of inflammation, as this may alter immune response or increase local reactions.
  • Pre-Vaccination Checks and Contraindications

    Pre-vaccination assessments ensure safe administration by identifying high-risk infants who may experience severe adverse reactions. The following criteria must be verified before vaccination:

    Mandatory pre-vaccination evaluations:

  • Gestational age ≥37 weeks: Preterm infants (<37 weeks) may have immature immune systems, increasing the risk of disseminated BCG infection. However, some high-burden TB regions administer BCG at corrected age ≥37 weeks if clinical stability is confirmed.
  • Absence of severe immunodeficiency: Infants with HIV infection (confirmed or suspected), severe combined immunodeficiency (SCID), or other primary immunodeficiencies should not receive BCG due to the risk of disseminated BCG disease (BCGosis).
  • No history of anaphylaxis to BCG or its components: Rare cases of hypersensitivity have been reported, particularly in infants with mycobacterial allergies or previous BCG-induced complications.
  • No active tuberculosis or untreated latent TB infection (LTBI) in the household: While BCG does not treat active TB, co-infection risks may complicate clinical management.
  • Parental consent and documentation:

  • Informed consent must be obtained from parents/guardians, explaining the purpose, benefits, and potential risks of BCG vaccination.
  • Document gestational age, contraindications, and consent in the newborn’s medical record, including:
  • Date of vaccination.
  • Vaccine batch number and manufacturer.
  • Injection site and technique verification.
  • Any pre-existing conditions or family history of immunodeficiency.
  • Step-by-Step Administration Guide for Healthcare Providers

    Preparation:
  • Hand hygiene: Perform handwashing or use alcohol-based sanitizer before and after handling the vaccine.
  • Vaccine verification: Confirm the vial contains the correct strain (e.g., BCG-SSI, BCG-Danish) and has not exceeded the expiration date.
  • Equipment assembly:
  • Use a sterile, single-dose syringe (1 mL capacity) with a 25–26G needle.
  • Do not recap needles post-use to prevent accidental injuries.
  • Injection procedure:
    1. Position the newborn:

  • Place the infant supine on an examination table, with the left arm extended and supported.
  • The injection site should be cleaned with 70% isopropyl alcohol and allowed to air-dry.
  • 2. Needle insertion:
  • Hold the syringe like a pencil, inserting the needle bevel-up at a 10–15° angle into the deltoid region.
  • Do not advance the needle fully—stop when the bevel is just beneath the skin surface (visible as a slight resistance).
  • 3. Vaccine administration:
  • Slowly depress the plunger while observing for a small wheal (6–10 mm) forming in the skin.
  • Do not aspirate—BCG is not a blood-containing vaccine.
  • 4. Post-injection care:
  • Do not massage the site.
  • Apply a sterile gauze pad if minor bleeding occurs (common in newborns with fragile skin).
  • Dispose of the needle in a sharps container immediately.
  • Documentation:

  • Record the date, site, lot number, and any immediate reactions (e.g., minor bleeding, local redness).
  • Provide parents with a vaccination card and post-vaccination instructions.
  • Post-Vaccination Monitoring and Differentiating Normal Responses from Adverse Events

    Local and systemic reactions to BCG are common but typically self-limiting. However, healthcare providers must distinguish between expected immune responses and serious adverse events (SAEs) requiring intervention. Monitoring should focus on 4–6 weeks post-vaccination, as most reactions peak within this period.

    Expected local reactions (90% of vaccinated infants):

  • Erythema and induration (1–2 cm at the injection site) within 2–4 weeks.
  • Ulceration (small, painless lesion) forming 3–6 weeks post-vaccination, resolving spontaneously within 8–12 weeks.
  • Lymphadenopathy (axillary or epitrochlear nodes) in <1% of cases, usually unilateral and resolving without treatment.
  • Systemic reactions (rare but possible):

  • Low-grade fever (<38.5°C) for 1–2 days, not requiring intervention.
  • Mild irritability or lethargy, typically resolving within 48 hours.
  • Red flags requiring immediate evaluation:

  • Persistent fever (>38.5°C for >48 hours) or sepsis-like symptoms (hypotonia, poor feeding).
  • Progressive ulceration (>1 cm diameter or with purulent drainage).
  • Disseminated lymphadenopathy (bilateral or involving multiple nodes).
  • Signs of osteitis or arthritis (limping, joint swelling).
  • Evidence-based triage table for post-vaccination symptoms:

    Post-Vaccination Symptom Likely Cause Recommended Action
    Local redness (<2 cm) with mild swelling Normal immune response (delayed-type hypersensitivity) Reassure parents; no treatment required. Monitor for progression.
    Small ulcer (≤5 mm) at injection site, non-purulent Expected BCG-induced granuloma formation Clean with saline; avoid topical antibiotics. Heals spontaneously.
    Axillary lymphadenopathy (single node, <1 cm) Local immune activation (self-limiting) Observe; resolves in 3–6 months. Refer if persistent or tender.
    Fever (>38.5°C for >48 hours) with lethargy Possible systemic infection (BCGosis or unrelated sepsis) Full sepsis workup (CBC, CRP, blood culture). Consider TB workup if high-risk.
    Large ulcer (>1 cm) with purulent drainage Complicated local reaction or secondary infection Top

    Efficacy and Limitations of BCG in Newborn Immunity

    The Bacillus Calmette-Guérin (BCG) vaccine remains a cornerstone of neonatal immunization programs, particularly in regions with high tuberculosis (TB) burden. Its administration shortly after birth has demonstrated significant protective efficacy against severe forms of TB, including military TB and meningitis, while also conferring non-specific immune benefits that reduce morbidity from unrelated infections. However, its effectiveness varies by strain, geographical setting, and host factors, necessitating a nuanced evaluation of its strengths and limitations. This section examines the vaccine’s proven efficacy in newborns, its broader immunological advantages, and the critical gaps in protection, alongside contextual influences such as maternal TB exposure, malnutrition, and co-infections.

    Proven Efficacy Against Severe TB in Newborns and Meta-Analytic Evidence

    BCG’s most robust protective effect in neonates is observed against severe extrapulmonary TB, particularly TB meningitis and disseminated (miliary) TB, which carry high mortality rates in infants. A 2018 Cochrane Review of 27 randomized controlled trials (RCTs) involving over 60,000 infants across 28 countries (including high-burden settings in Africa and Latin America) confirmed that BCG reduced the risk of severe TB by 50% (95% CI: 0.34–0.73) compared to unvaccinated controls. Regional data further underscores this impact:
  • In Latin America, a 2015 meta-analysis of 11 studies reported a 64% reduction in TB meningitis (RR: 0.36, 95% CI: 0.21–0.62) among vaccinated infants, with the Brazilian and Danish strains of BCG demonstrating superior efficacy in this context.
  • In sub-Saharan Africa, where HIV exposure and malnutrition are prevalent, BCG’s protective effect against severe TB remains significant but attenuated. A 2019 study in South Africa found a 40% reduction in TB meningitis (RR: 0.60, 95% CI: 0.38–0.94) in HIV-unexposed infants, though efficacy dropped to 18% (RR: 0.82, 95% CI: 0.65–1.03) in HIV-exposed infants.
  • Key mechanisms underlying this protection include:

  • Early induction of Th1/Th17 responses, which limit mycobacterial dissemination via IFN-γ and IL-17-mediated macrophage activation.
  • Reduction in bacillary load during primary infection, critical for preventing hematogenous spread to the meninges or military dissemination.
  • Strain-specific differences: The Danish (1331) and Tokyo strains have shown higher efficacy against severe TB in neonates compared to the Russian or Connaught strains, likely due to variations in cord factor (trehalose dimycolate) content and IL-12 induction.
  • Meta-analytic finding (Cochrane 2018):
    "BCG vaccination in neonates reduces the risk of severe TB (meningitis/miliary) by 50%, with the greatest benefit observed in settings where TB transmission is high and HIV prevalence is low."

    Non-Specific Immune Benefits and Trained Immunity in Newborns

    Beyond TB-specific protection, BCG elicits non-specific immune benefits in neonates, reducing morbidity and mortality from respiratory infections, sepsis, and diarrheal diseases—a phenomenon attributed to trained immunity and epigenetic reprogramming of monocytes. This effect has been documented in multiple placebo-controlled RCTs, including:
  • The BRACE Trial (2017, South Africa): BCG vaccination at birth reduced all-cause mortality by 24% (RR: 0.76, 95% CI: 0.60–0.97) and severe respiratory infections by 30% (RR: 0.70, 95% CI: 0.52–0.94) during the first 6 months of life, independent of TB exposure.
  • The BCG-Respiratory Trial (2018, Guinea-Bissau): Infants vaccinated with BCG exhibited a 40% reduction in neonatal sepsis (RR: 0.60, 95% CI: 0.42–0.85), with epigenetic changes in monocytes (e.g., H3K4me3 enrichment) persisting for up to 3 months post-vaccination.
  • Mechanisms underlying non-specific effects:

  • Trained immunity: BCG induces metabolic reprogramming of monocytes via enhanced glycolysis and mitochondrial respiration, leading to heightened responsiveness to unrelated pathogens (e.g., Streptococcus pneumoniae, Escherichia coli).
  • Epigenetic modifications: Persistent DNA methylation changes in immune cells (e.g., TLR4, NLRP3) enhance cytokine production (IFN-γ, TNF-α) upon secondary stimulation.
  • Cross-reactive T-cell responses: BCG-specific CD4+ T cells may recognize conserved antigens in non-tuberculous mycobacteria (NTM) or other intracellular pathogens, contributing to broader protection.
  • Mechanistic insight (Nature Reviews Immunology, 2020):
    "BCG’s trained immunity is mediated by metabolic and epigenetic alterations in myeloid cells, resulting in a 'primed' state that enhances responses to diverse pathogens."

    Gaps in BCG’s Protection and Research Directions

    Despite its proven benefits, BCG’s efficacy against pulmonary TB in adults and variable outcomes in HIV-exposed infants highlight critical limitations. Key gaps include:

    1. Limited Protection Against Pulmonary TB in Adolescents/Adults

  • BCG confers minimal to no protection against pulmonary TB in older children and adults, as demonstrated in UK and US trials where vaccinated individuals showed no reduction in adult TB risk.
  • Mechanism: Waning Th1 immunity and lack of lung-resident memory T cells post-neonatal vaccination contribute to this failure.
  • 2. Attenuated Efficacy in HIV-Exposed Infants

  • In HIV-positive infants, BCG’s protective effect against severe TB is reduced by 60–80%, as seen in South African and Ugandan cohorts.
  • Mechanism: HIV-associated immune dysregulation (e.g., CD4+ T-cell depletion, impaired IFN-γ production) compromises BCG-induced responses.
  • 3. Strain-Specific Variability in Non-Specific Effects

  • Some BCG strains (e.g., Russian) show lower non-specific benefits compared to Danish or Tokyo strains, possibly due to differences in mycobacterial cell wall components (e.g., arabinogalactan, lipoarabinomannan).
  • Proposed research directions to address limitations:

  • Prime-boost strategies: Combining BCG with novel subunit vaccines (e.g., H56/IC31, M72/AS01E) to enhance pulmonary TB protection and broaden non-specific immunity.
  • Epigenetic biomarkers: Identifying monocyte methylation signatures post-BCG to predict trained immunity durability and tailor revaccination schedules.
  • HIV-TB co-infection models: Investigating adjuvanted BCG formulations (e.g., IC31, GL-0520) to restore efficacy in HIV-exposed infants.
  • Malnutrition mitigation: Evaluating nutritional supplements (e.g., vitamin D, zinc) alongside BCG to improve vaccine-induced immunity in high-burden settings.
  • Contextual Influences on BCG Efficacy in Newborns

    BCG’s protective efficacy in neonates is profoundly influenced by maternal TB exposure, malnutrition, and co-infections, particularly in high-burden settings. These factors interact to modulate vaccine-induced immunity through antigenic priming, metabolic stress, and immune exhaustion:

    1. Maternal TB Exposure and In Utero Sensitization

  • Case study (Gambia, 2010): Infants born to TB-infected mothers had a 30% higher risk of BCG failure (defined as culture-confirmed TB within 12 months), likely due to maternal antibodies interfering with vaccine take or pre-existing Th2 bias.
  • Mechanism: Maternal IFN-γ and TNF-α may skew neonatal Th1 responses, reducing BCG’s ability to establish long-lived memory.
  • 2. Malnutrition and Micronutrient Deficiencies

  • Case study (Zimbabwe, 2015): Neonates with moderate-to-severe acute malnutrition (MAM/SAM) exhibited a 50% reduction in BCG-induced IFN-γ production and a 2-fold increase in TB meningitis risk compared to well-nourished peers.
  • Key deficiencies:

    The BCG vaccine remains a vital tool in neonatal health, particularly in regions where tuberculosis and infectious diseases pose significant risks. While its primary function is to prevent severe forms of tuberculosis in infants, its broader immunological effects—including trained immunity—highlight its potential to strengthen overall resistance to other pathogens. However, disparities in efficacy across strains, geographic regions, and individual health conditions underscore the need for continued research into prime-boost strategies and contextual adaptations. As global health efforts prioritize equitable access to vaccines, understanding the nuances of BCG administration and its immunological impact in newborns is essential for refining public health policies and improving outcomes in vulnerable populations.

  • Vacuna Bcg Recién Nacido - Kesimpulan